Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Adocia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adocia Initiates Phase 2 Clinical Trial for M1Pram in Patients with Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Peptide","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II"},{"orgOrder":0,"company":"Adocia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adocia Expands Clinical Development to Obesity with Patent Applications on Short-Acting Multihormonal Combinations Administered by Pumps","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Peptide","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical"},{"orgOrder":0,"company":"Adocia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adocia Initiates BC LisPram Phase 1 Clinical Trial in Pump for People with Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Peptide","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I"},{"orgOrder":0,"company":"Adocia","sponsor":"Tonghua Dongbao Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adocia\u2019s partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone\u00ae Lispro Phase 3 Trial to Treat Type 1 and Type 2 Diabetes in China","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Peptide","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by Adocia

    Menu

    Adocia

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Adocia

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Adocia’s partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone® Lispro Phase 3 Trial to Treat Type 1 and Type 2 Diabetes in China

              Details:

              The primary objective of Phase 3 program is to demonstrate non-inferiority of BC Lispro on HbA1c reduction from baseline vs. Humalog. BioChaperone® Lispro (BC Lispro) is ultra-rapid prandial insulin containing insulin lispro and Adocia’s proprietary technology BioChaperone®.

              Lead Product(s): Insulin Lispro

              Therapeutic Area: Endocrinology Product Name: BioChaperone Lispro

              Highest Development Status: Phase I Product Type: Peptide

              Recipient: Tonghua Dongbao Pharma

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 14, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Adocia

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Adocia Initiates BC LisPram Phase 1 Clinical Trial in Pump for People with Type 1 Diabetes

              Details:

              Pramlintide, despite being the only drug approved as an adjunct to insulin in type 1 diabetes, is underused as it requires three additional daily injections in addition to the multiple injections of insulin.

              Lead Product(s): Insulin Lispro,Pramlintide

              Therapeutic Area: Endocrinology Product Name: BC LisPram

              Highest Development Status: Phase I Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 29, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Adocia

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Adocia Expands Clinical Development to Obesity with Patent Applications on Short-Acting Multihormonal Combinations Administered by Pumps

              Details:

              Three patent families have been filed to cover novel hormonal combinations: pramlintide-exenatide and glucagon-exenatide-both combinations demonstrated promising effects in obesity treatment.

              Lead Product(s): Pramlintide,Exenatide

              Therapeutic Area: Nutrition and Weight Loss Product Name: PramExe

              Highest Development Status: Preclinical Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 26, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Adocia

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Adocia Initiates Phase 2 Clinical Trial for M1Pram in Patients with Type 1 Diabetes

              Details:

              The purpose of the study is to confirm and optimize the safety and efficacy of M1Pram in comparison with insulin lispro (Humalog®, Eli Lilly) in regard to glycemic control and body weight reduction.

              Lead Product(s): Insulin Lispro

              Therapeutic Area: Endocrinology Product Name: M1 Pram P037

              Highest Development Status: Phase II Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 10, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY